

according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 04/04/2023 |
|---------|----------------|---------------|---------------------------------|
| 3.8 | 09/30/2023 | 1732000-00013 | Date of first issue: 06/05/2017 |

SECTION 1. IDENTIFICATION

| Product name | : | Fidaxomicin Formulation |
|-------------------------------|---|-------------------------|
| Other means of identification | : | No data available |

Manufacturer or supplier's details

| : | Merck & Co., Inc |
|---|---------------------------------|
| : | 126 E. Lincoln Avenue |
| | Rahway, New Jersey U.S.A. 07065 |
| : | 908-740-4000 |
| : | 1-908-423-6000 |
| : | EHSDATASTEWARD@merck.com |
| | : |

Recommended use of the chemical and restrictions on use

| Recommended use | : | Pharmaceutical |
|---------------------|---|----------------|
| Restrictions on use | : | Not applicable |

SECTION 2. HAZARDS IDENTIFICATION

| GHS classification in accordance with the Hazardous Products Regulations | | | | | |
|--|---|------------|--|--|--|
| Acute toxicity (Oral) | : | Category 4 | | | |

GHS label elements

Hazard pictograms:Image: Constraint of the systemSignal Word:WarningHazard Statements:H302 Harmful if swallowed.Precautionary Statements:Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel
unwell. Rinse mouth.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| ersion Revision Date: 8 09/30/2023 | | SDS Num 1732000-0 | 2011 | e of last issue: 04/04/2023 e of first issue: 06/05/2017 |
|---------------------------------------|-----------------|------------------------|-------------|---|
| Subs | tance / Mixture | : Mixture | 9 | |
| Com | ponents | | | |
| Chemical name | | Common Name/Synonym | CAS-No. | Concentration (% w/w) |
| Fidaxomicin | | No data availa- ble | 873857-62-6 | >= 40 - <= 60 |
| Cellulose | | No data availa- ble | 9004-34-6 | >= 15 - <= 30 |
| Starc | h | Sago starch | 9005-25-8 | >= 5 - <= 15 |

| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
|---|---|--|
| If inhaled | : | If inhaled, remove to fresh air. Get medical attention if symptoms occur. |
| In case of skin contact | : | Wash with water and soap as a precaution. Get medical attention if symptoms occur. |
| In case of eye contact | : | Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

| Suitable extinguishing media | : | Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical |
|--|---|--|
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion prod- ucts | : | Carbon oxides |
| Specific extinguishing meth- ods | : | Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. |



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Versior 3.8 | n | Revision Date: 09/30/2023 | | DS Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 | | |
|---|-------|--|--|---|--|--|--|
| Special protective equipment for fire-fighters | | | | so. Evacuate area. In the event of fire | ged containers from fire area if it is safe to do e, wear self-contained breathing apparatus. sective equipment. | | |
| SECTI | ION 6 | . ACCIDENTAL RELE | AS | E MEASURES | | | |
| Personal precautions, protec- tive equipment and emer- gency procedures | | | : | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). | | | |
| Environmental precautions | | : | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. | | | | |
| | | ls and materials for ment and cleaning up | : | container for disp Local or national disposal of this m employed in the c determine which in Sections 13 and 1 | tum up spillage and collect in suitable osal. regulations may apply to releases and aterial, as well as those materials and items leanup of releases. You will need to regulations are applicable. 5 of this SDS provide information regarding tional requirements. | | |

SECTION 7. HANDLING AND STORAGE

| Technical measures | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. | |
|--|---|---|
| Local/Total ventilation Advice on safe handling | Use only with adequate ventilation. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safe practice, based on the results of the workplace exposure assessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to environment. | |
| Conditions for safe storage | Keep in properly labeled containers. | |
| Materials to avoid | Store in accordance with the particular national regulations Do not store with the following product types: Strong oxidizing agents | • |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type | Control parame- | Basis |
|------------|---------|------------|-----------------|-------|
| | | | | |




according to the Hazardous Products Regulations

Fidaxomicin Formulation

| rsion | Revision Date: 09/30/2023 | SDS Numbe 1732000-00 | | st issue: 04/04/2023 st issue: 06/05/2017 | | |
|---------|------------------------------|-------------------------|--|--|-----------|--|
| | | | (Form of exposure) | ters / Permissible concentration | | |
| Fidaxo | omicin | 873857-6 | 52-6 TWA | 200 µg/m3 (OEB 2) | Internal | |
| Cellulo | ose | 9004-34- | 6 TWA | 10 mg/m ³ | CA AB OEL | |
| | | | TWA (Total dust) | 10 mg/m ³ | CA BC OEL | |
| | | | TWA (respir- able dust fraction) | 3 mg/m ³ | CA BC OEL | |
| | | | TWAEV (to- tal dust) | 10 mg/m ³ | CA QC OEL | |
| | | | TWA | 10 mg/m ³ | ACGIH | |
| Starch | l | 9005-25- | 8 TWA | 10 mg/m³ | CA AB OEL | |
| | | | TWA (Total dust) | 10 mg/m ³ | CA BC OEL | |
| | | | TWA (respir- able dust fraction) | 3 mg/m ³ | CA BC OEL | |
| | | | TWAEV (to- tal dust) | 10 mg/m ³ | CA QC OEL | |
| | | | TWA | 10 mg/m ³ | ACGIH | |
| C | eering measures | Minimize | adequate ventilation, workplace exposure | especially in confine e concentrations. | d areas. | |
| Perso | nal protective equip | ment | | | | |
| Respir | atory protection | exposure | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. | | | |
| | er type protection | : Particula | | ,, , , | | |
| Ma | terial | : Chemica | al-resistant gloves | | | |

| Remarks | : | Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday. |
|--|---|---|
| Eye protection | : | Wear the following personal protective equipment: Safety glasses |
| Skin and body protection Hygiene measures | | Skin should be washed after contact. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES





Fidaxomicin Formulation

| Version 3.8 | Revision Date: 09/30/2023 | | S Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|----------------|--|---|-----------------------------------|---|
| Ap | pearance | : | solid | |
| Co | lor | : | white to off-white | |
| Od | or | : | No data available |) |
| Od | or Threshold | : | No data available | 9 |
| pН | | : | Not applicable | |
| Me | Iting point/freezing point | : | 175 - 185 °C Active ingredient | |
| Init rar | ial boiling point and boiling ge | : | Not applicable | |
| Fla | sh point | : | Not applicable | |
| Eva | aporation rate | : | No data available |) |
| Fla | mmability (solid, gas) | : | Not classified as | a flammability hazard |
| Fla | mmability (liquids) | : | No data available |) |
| | per explosion limit / Upper nmability limit | : | No data available | |
| | wer explosion limit / Lower mmability limit | : | No data available | |
| Va | por pressure | : | No data available | |
| Re | lative vapor density | : | No data available | |
| De | nsity | : | No data available | |
| | lubility(ies) Water solubility | : | No data available |) |
| | rtition coefficient: n- anol/water | : | log Pow: 4.4 Active ingredient | |
| Au | toignition temperature | : | No data available | |
| De | composition temperature | : | No data available | |
| Vis | cosity Viscosity, kinematic | : | No data available |) |
| Ex | plosive properties | : | Not explosive | |
| Ox | idizing properties | : | The substance o | r mixture is not classified as oxidizing. |

according to the Hazardous Products Regulations



Fidaxomicin Formulation

| Version 3.8 | Revision Date: 09/30/2023 | SDS Number: 1732000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|----------------|------------------------------|------------------------------|---|
| Moleo | cular weight | : Not applicable | |
| Partic | cle size | : No data availab | le |
| | | | |

SECTION 10. STABILITY AND REACTIVITY

| Reactivity Chemical stability Possibility of hazardous reac- tions | : | Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents. |
|--|---|--|
| Conditions to avoid Incompatible materials Hazardous decomposition products | | None known. Oxidizing agents No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION

| Information on likely routes Skin contact Ingestion Eye contact | of | exposure |
|--|----|--|
| Acute toxicity Harmful if swallowed. | | |
| Product: Acute oral toxicity | : | Acute toxicity estimate: 833.33 mg/kg Method: Calculation method |
| Components: | | |
| Fidaxomicin: | | |
| Acute oral toxicity | : | LD50 (Rat): > 1,000 mg/kg |
| | | LD50 (Dog): > 120 mg/kg |
| Acute toxicity (other routes of administration) | : | LD50 (Rat): 200 mg/kg Application Route: Intravenous |
| Cellulose: | | |
| Acute oral toxicity | : | LD50 (Rat): > 5,000 mg/kg |
| Acute inhalation toxicity | : | LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist |
| Acute dermal toxicity | : | LD50 (Rabbit): > 2,000 mg/kg |
| Starch: | | |
| Acute oral toxicity | : | LD50 (Rat): > 5,000 mg/kg |



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Vers 3.8 | sion | Revision Date: 09/30/2023 | - | 9S Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|-------------|------------------|--|--------|---|---|
| | Acute | dermal toxicity | : | LD50 (Rabbit): > | 2,000 mg/kg |
| | | orrosion/irritation ssified based on avai | ilable | information. | |
| | | s eye damage/eye in ssified based on avai | | | |
| | Comp | onents: | | | |
| | Starch | : | | | |
| | Specie Result | S | : | Rabbit No eye irritation | |
| | Respir | atory or skin sensit | izatio | n | |
| | | ensitization ssified based on avai | ilable | information. | |
| | Respir | atory sensitization | | | |
| | Not cla | ssified based on avai | ilable | information. | |
| | Comp | onents: | | | |
| | Starch | : | | | |
| | Test Ty | /pe s of exposure | : | Maximization Tes Skin contact | st |
| | Specie | | : | Guinea pig | |
| | Result | | : | negative | |
| | Germ | cell mutagenicity | | | |
| | | ssified based on avai | ilable | information. | |
| | Comp | onents: | | | |
| | Fidaxo | omicin: | | | |
| | | oxicity in vitro | : | Test Type: Bacte Result: negative | rial reverse mutation assay (AMES) |
| | | | | | nosome aberration test in vitro nese hamster ovary cells |
| | Genoto | oxicity in vivo | : | Test Type: Mamr cytogenetic assay Species: Rat Application Route Result: negative | |

Test Type: comet assay Species: Rat Result: negative



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| rsion S | Revision Date: 09/30/2023 | | S Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 | | |
|------------------|--|-----|---|---|--|--|
| Cellul | ose: | | | | | |
| Genote | oxicity in vitro | : | Test Type: Bacte Result: negative | pe: Bacterial reverse mutation assay (AMES) negative | | |
| | | | Test Type: In vitre Result: negative | o mammalian cell gene mutation test | | |
| Genote | oxicity in vivo | : | Test Type: Mamr cytogenetic assay Species: Mouse Application Route Result: negative | | | |
| Starch | 1: | | | | | |
| Genote | oxicity in vitro | : | Test Type: Bacte Result: negative | rial reverse mutation assay (AMES) | | |
| | nogenicity assified based on availa | blo | information | | | |
| | onents: | bie | iniomation. | | | |
| - | | | | | | |
| Cellul Specie | | | Rat | | | |
| | ation Route | ÷ | Ingestion | | | |
| Expos Result | ure time | : | 72 weeks negative | | | |
| Repro | ductive toxicity | | | | | |
| Not cla | assified based on availa | ble | information. | | | |
| <u>Comp</u> | onents: | | | | | |
| Fidaxo | omicin: | | | | | |
| Effects | s on fertility | : | | y/early embryonic development | | |
| | | | Species: Rat | | | |
| | | | | · Intravenous injection | | |
| | | | Application Route | e: Intravenous injection 6.3 mg/kg body weight | | |
| Effects | s on fetal development | : | Application Route Fertility: NOAEL: | | | |
| Effects | s on fetal development | : | Application Route Fertility: NOAEL: Test Type: Embry Species: Rat | 6.3 mg/kg body weight vo-fetal development | | |
| Effects | s on fetal development | : | Application Route Fertility: NOAEL: Test Type: Embry Species: Rat Application Route Developmental T | 6.3 mg/kg body weight | | |
| Effects | on fetal development | : | Application Route Fertility: NOAEL: Test Type: Embry Species: Rat Application Route Developmental T Remarks: No sign Test Type: Embry | 6.3 mg/kg body weight vo-fetal development e: Intravenous injection oxicity: NOAEL: 12.6 mg/kg body weight | | |
| Effects | s on fetal development | : | Application Route Fertility: NOAEL: Test Type: Embry Species: Rat Application Route Developmental T Remarks: No sign Test Type: Embry Species: Rabbit | 6.3 mg/kg body weight vo-fetal development e: Intravenous injection oxicity: NOAEL: 12.6 mg/kg body weight hificant adverse effects were reported | | |

Cellulose:



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Vers 3.8 | ion | Revision Date: 09/30/2023 | | 9S Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|-------------|---------|---|-----|---|---|
| | Effects | on fertility | : | Test Type: One-g Species: Rat Application Route Result: negative | eneration reproduction toxicity study : Ingestion |
| | Effects | on fetal development | : | Test Type: Fertility Species: Rat Application Route Result: negative | y/early embryonic development : Ingestion |
| | | single exposure ssified based on availa | ble | information. | |
| | | repeated exposure ssified based on availa | ble | information. | |
| | Repea | ted dose toxicity | | | |
| | Compo | onents: | | | |
| | Fidaxo | omicin: | | | |
| | Specie | | : | Rat | |
| | NOAEI | | : | 90 mg/kg | |
| | | ation Route | ÷ | Oral | |
| | Remar | ure time | ÷ | 28 D | area offacts were reported |
| | Reman | KS | • | No significant adv | erse effects were reported |
| | Specie | S | : | Rat | |
| | NOAEL | | : | 62.5 mg/kg | |
| | | ation Route | : | Intravenous | |
| | Exposu | ure time | : | 14 D | |
| | Specie | S | : | Dog | |
| | NOAEL | | ÷ | 9,600 mg/kg | |
| | | ation Route | : | Oral | |
| | | ure time | : | 3 M | |
| | Sympto | | : | Vomiting | <i>"</i> · · · · · |
| | Remar | KS | : | No significant adv | erse effects were reported |
| | Specie | S | : | Monkey | |
| | NOAEL | | : | 90 mg/kg | |
| | | ation Route | : | Oral | |
| | | ure time | : | 28 D | |
| | Remar | ks | : | No significant adv | erse effects were reported |
| | Specie | S | : | Juvenile rat | |
| | NOAEL | | : | 200 mg/kg | |
| | Applica | ation Route | : | Oral | |
| | | ure time | : | 28 D | |
| | Remar | ks | : | No significant adv | erse effects were reported |
| | Cellulo |)se: | | | |
| | Specie | | : | Rat | |
| | Opecie | 0 | · | nat | |
| | | | | | |



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Versio 3.8 | on | Revision Date: 09/30/2023 | - | DS Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|------------------|-------------------|---|-----|--|---|
| A | | - ition Route ire time | : | >= 9,000 mg/kg Ingestion 90 Days | |
| S N A E | | s - ition Route ure time | : | Rat >= 2,000 mg/kg Skin contact 28 Days OECD Test Guide | eline 410 |
| Ν | Not cla | tion toxicity ssified based on availa | | | |
| | • | ence with human exp | osi | lre | |
| F | | onents: micin: on | : | Symptoms: Abdor | minal pain, Nausea, Vomiting, constipation |
| SECT | FION 1 | 2. ECOLOGICAL INFO | ORN | MATION | |
| E | Ecotox | kicity | | | |
| <u>c</u> | Compo | onents: | | | |
| Т | | micin: / to algae/aquatic | : | Exposure time: 72 Method: OECD T | |
| | | | | Exposure time: 72 Method: OECD T | |
| | Foxicity city) | / to fish (Chronic tox- | : | Exposure time: 32 Method: OECD T | |
| а | | / to daphnia and other invertebrates (Chron- ity) | : | NOEC (Daphnia r Exposure time: 2 ⁴ Method: OECD T | |
| Т | Foxicity | / to microorganisms | : | EC50: > 50 mg/l Exposure time: 3 Test Type: Respir Method: OECD T | ation inhibition |
| | | | | NOEC: 5.9 mg/l | |



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| Version 3.8 | Revision Date: 09/30/2023 | | DS Number: 32000-00013 | Date of last issue: 04/04/2023 Date of first issue: 06/05/2017 |
|----------------|--|-----|---|--|
| | | | Exposure time: 3 Test Type: Respir Method: OECD T | ration inhibition |
| Cel | lulose: | | | |
| Тох | icity to fish | : | Exposure time: 48 | ipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials |
| Per | sistence and degradabil | ity | | |
| <u>Cor</u> | nponents: | | | |
| Cel | lulose: | | | |
| Biod | degradability | : | Result: Readily bi | iodegradable. |
| Bio | accumulative potential | | | |
| <u>Cor</u> | nponents: | | | |
| Par | axomicin: tition coefficient: n- anol/water | : | log Pow: 4.4 | |
| Mol | bility in soil | | | |
| Cor | nponents: | | | |
| Dist | axomicin: tribution among environ- ntal compartments | : | log Koc: 0.80 | |
| | er adverse effects data available | | | |
| SECTIO | N 13. DISPOSAL CONSII | DEF | RATIONS | |

| Disposal methods | | |
|------------------------|---|--|
| Waste from residues | : | Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good



according to the Hazardous Products Regulations

Fidaxomicin Formulation

| 3.8 09/30/2023 1732000-00013 Date of first issue: 06/05/2017 | Version | Revision Date: | SDS Number: | Date of last issue: 04/04/2023 |
|--|---------|----------------|---------------|---------------------------------|
| | 3.8 | 09/30/2023 | 1732000-00013 | Date of first issue: 06/05/2017 |

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

| AICS | : | not determined |
|-------|---|----------------|
| DSL | : | not determined |
| IECSC | : | not determined |

SECTION 16. OTHER INFORMATION

| Full text of other abbreviations | | | | |
|----------------------------------|---|---|--|--|
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) | | |
| CA AB OEL | : | Canada. Alberta, Occupational Health and Safety Code (table 2: OEL) | | |
| CA BC OEL | : | Canada. British Columbia OEL | | |
| CA QC OEL | : | Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants | | |
| ACGIH / TWA | : | 8-hour, time-weighted average | | |
| CA AB OEL / TWA | : | 8-hour Occupational exposure limit | | |
| CA BC OEL / TWA | | 8-hour time weighted average | | |
| CA QC OEL / TWAEV | : | Time-weighted average exposure value | | |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-



Fidaxomicin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 04/04/2023 |
|---------|----------------|---------------|---------------------------------|
| 3.8 | 09/30/2023 | 1732000-00013 | Date of first issue: 06/05/2017 |

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

| Sources of key data used to compile the Material Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/ |
|--|---|--|
| Revision Date Date format | : | 09/30/2023 mm/dd/yyyy |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8